Issued on behalf of VentriPoint Diagnostics Ltd.
VANCOUVER, Baystreet.ca News Commentary – Heart disease is still the number one killer in the US. Despite decades of medical progress, massive gaps in basic care and treatment access remain a critical issue[1]. Now, major global health authorities are stepping in. Just last month, the World Heart Federation urged WHO leaders to rapidly scale up diagnostic infrastructure in overlooked regions and secure sustainable funding[2]. This pivotal shift is creating a highly scalable environment for capital. Investors are moving decisively into the cardiac space to fund everything from early AI detection to advanced late-stage therapies. Positioned right at the center of this undervalued opportunity are VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Merck (NYSE: MRK), Viatris (NASDAQ: VTRS), United Therapeutics (NASDAQ: UTHR), and Edwards Lifesciences (NYSE: EW).
The numbers backing this structural shift are impossible to ignore. The global AI cardiology market is currently valued at roughly $2.78 billion in 2026 and is projected to reach an impressive $14.22 billion by 2034[3]. Health systems are scrambling to automate workflows and bring remote cardiac assessments to the masses. Peer-reviewed clinical data shows that the global burden of heart failure is accelerating rapidly. The sharpest growth is hitting low and middle-income regions the hardest. Because these areas lack basic diagnostic access, diagnostic democratization and targeted therapies have emerged as the dominant value drivers of this current market cycle[4].
VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is expanding into remote healthcare after announcing a partnership with First Light Health, an Indigenous-owned medical services company based in Vancouver, to deliver AI-powered cardiac diagnostics to Indigenous and remote communities across Canada.
Together, the two companies are developing a hub-and-spoke care model built around VentriPoint's VMS+™ system. Local providers in remote areas will capture ultrasound scans on-site and be supported by specialists at a central hub who are able to digitally access images and assist with interpretation. That gives patients in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick access to advanced cardiac imaging without travelling hundreds of kilometres, at lower cost and with faster turnaround than traditional referral pathways. Following validation of the model, Ventripoint plans to scale it beyond Canada into underserved communities globally.
VentriPoint’s VMS+™ system converts standard 2D echocardiograms into detailed 3D volumetric images. The company says its accuracy is comparable to cardiac MRI, but at a fraction of the cost and without the infrastructure those machines require. For communities where heart disease rates are high and specialist access is limited, the difference between early diagnosis and late diagnosis can be the difference between treatment and tragedy.
"Cardiovascular disease doesn't respect geography, but too often, access to cardiac care does," said Hugh MacNaught, CEO of VentriPoint Diagnostics. "Our work with First Light Health and other First Nations partners such as the Nisga_'a Valley Health Authority demonstrates the need for a made-in-Canada innovation that can close that gap. We see the potential for this solution to be widely deployed, from the Arctic to the Amazon. This is what scalable, equitable heart care looks like."
First Light Health brings cultural safety expertise and established relationships within First Nations communities, which matters when deploying health technology in populations that have historically been underserved by the broader system.
The partnership builds on recent commercial traction. VentriPoint signed a commercial agreement with LG Consulting Solutions to support VMS+™ deployment across Northern California, targeting cardiac centres in the Sacramento and San Francisco regions. Before that, the company had already partnered with the Nisga_'a Valley Health Authority to pilot a similar model in northern BC.
VentriPoint is a Toronto-based medtech company with regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform works with ultrasound equipment from any vendor and is built on over a decade of Knowledge Based Reconstruction technology development. The goal is simple: put MRI-grade cardiac diagnostics within reach of any clinic or community that needs them.
CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint
In other industry developments and happenings in the market include:
Merck (NYSE: MRK) presented late-breaking cardio-pulmonary data at ACC.26 featuring positive Phase 3 results from the CORALreef AddOn trial of enlicitide decanoate, an investigational once-daily oral PCSK9 inhibitor with the potential to be the first approved therapy of its kind, alongside Phase 2 CADENCE data for WINREVAIR (sotatercept-csrk) in combined post- and precapillary pulmonary hypertension with heart failure with preserved ejection fraction. Enlicitide has now demonstrated statistically significant LDL-C reductions across three pivotal studies and is continuing evaluation in the large CORALreef Outcomes cardiovascular outcomes trial with over 14,500 enrolled participants.
"The data planned for presentation at ACC will underscore the strength and momentum of Merck's cardio-pulmonary pipeline as we work to advance research that helps address the CV epidemic impacting millions with atherosclerosis, as well as CpcPH-HFpEF, a distinct syndrome with limited treatment options," said Dr. Joerg Koglin, Senior Vice President, Head of General and Specialty Medicine, Global Clinical Development, Merck Research Laboratories. "Building on our history of bringing forward innovative therapies in heart and lung disease, we are proud to share research at ACC.26 that improves our understanding of these serious diseases and has the potential to help patients around the world."
WINREVAIR is already FDA-approved for pulmonary arterial hypertension, and positive CADENCE data expand its potential into CpcPH-HFpEF, a condition with no currently approved treatments. Merck's cardiovascular franchise spans hypercholesterolemia, pulmonary hypertension, and COPD, with multiple late-stage programs advancing simultaneously.
Viatris (NASDAQ: VTRS) launched Inpefa (sotagliflozin) in the United Arab Emirates, becoming the first country within Viatris territories to commercialize the world's only dual SGLT1/2 inhibitor approved for heart failure. The approval is backed by two pivotal Phase 3 trials enrolling more than 11,800 patients, with Inpefa reducing composite cardiovascular risk by 33% in SOLOIST-WHF and 25% in SCORED.
"The launch of Inpefa in the UAE marks another important step as we continue to deliver innovative medicines for patients around the world," said Corinne Le Goff, Chief Commercial Officer of Viatris. "Heart failure is the world's leading cause of hospitalization, and as such there is an ongoing need for new treatments to help address this burden."
With regulatory filings already submitted in Canada, Australia, and Mexico, Viatris is advancing a multi-market commercialization strategy for Inpefa over the next several years. The company's broader innovative pipeline includes several late-stage programs advancing in parallel to support long-term cardiovascular franchise growth.
United Therapeutics (NASDAQ: UTHR) announced full publication of its TETON-2 Phase 3 results in The New England Journal of Medicine, demonstrating that nebulized Tyvaso (treprostinil) preserved lung function versus placebo over 52 weeks in idiopathic pulmonary fibrosis patients, with a between-group FVC difference of 95.6 mL and a 29% reduction in clinical worsening events. The study is the first to show an inhaled therapy slowing IPF progression across all patient subgroups, with 75% of participants on background antifibrotic therapy.
"The publication of TETON-2 in The New England Journal of Medicine marks a pivotal moment for the IPF community," said Martine Rothblatt, Chairperson and CEO of United Therapeutics. "For too long, patients have had limited options to treat this devastating disease. Nebulized Tyvaso has the potential to be the first and only inhaled anti-fibrotic treatment for IPF — a true advancement for patients and physicians alike."
United Therapeutics plans to submit a supplemental New Drug Application to the FDA in the second half of 2026 pending results from the companion TETON-1 study, which are expected soon. Both the FDA and the European Medicines Agency have granted orphan designation for treprostinil in IPF, supporting an accelerated regulatory path.
Edwards Lifesciences (NYSE: EW) reaffirmed its structural heart leadership at the close of Heart Month, announcing a renewed commitment through its Every Heartbeat Matters initiative targeting 2 million additional underserved patients by 2030. Since 2014, the program and its charitable partners have reached more than 4 million structural heart patients in low- and middle-income countries.
"For nearly 70 years, Edwards has led with a strong focus on improving the lives of patients with structural heart disease," said Bernard Zovighian, CEO of Edwards Lifesciences. "It starts with breakthrough innovation, layered with world class clinical expertise, sustained commitment and strong partnerships across the global healthcare ecosystem. Every advancement we make impacts a patient, a family and a community. Our purpose is to advance science and expand access so more people can benefit."
Edwards Lifesciences continues to invest in expanding access beyond commercially developed markets, working to dismantle financial, systemic, and geographic barriers that prevent underserved patients from receiving structural heart care. The company's Foundation and global partner network anchor a long-term access strategy that complements its clinical innovation pipeline.
Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint
CONTACT:
Baystreet.ca
[email protected]
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as
personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is owned by Baystreet.ca Media Corp. (BAY). BAY has been paid a fee of for GoldHaven Resources Corp. advertising and digital media for this article. There may be 3rd parties who may have shares of GoldHaven Resources Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly
encouraged to not use this publication as the basis for any investment decision. The owner/operator (BAY); reserve the right to buy and sell, and will buy and sell shares of GoldHaven Resources Corp. at any time without any further notice commencing immediately and ongoing.We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by GoldHaven Resources Corp. Technical information relating to GoldHaven Resources Corp. has been reviewed and approved by Jonathan Victor Hill, B.Sc. Hons, FAusIMM, a Qualified Person consistent with NI 43-101 and Country Manager of GoldHaven, and therefore is not independent of the Company; While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCES:
1. https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027
2. https://world-heart-federation.org/news/advancing-ambitious-ncd-and-cardiovascular-agendas-at-who-executive-board-158/
3. https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767
4. https://academic.oup.com/eschf/article/13/1/xvag038/8439119
